Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Autolus Therapeutics PLC

2.41
-0.0500-2.03%
Post-market: 2.410.00000.00%19:44 EDT
Volume:2.41M
Turnover:5.85M
Market Cap:641.41M
PE:-2.29
High:2.51
Open:2.47
Low:2.40
Close:2.46
52wk High:2.58
52wk Low:1.18
Shares:266.14M
Float Shares:118.00M
Volume Ratio:0.61
T/O Rate:2.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0526
EPS(LYR):-1.0804
ROE:-133.00%
ROA:-25.44%
PB:8.57
PE(LYR):-2.23

Loading ...

OverviewCompanyNewsFilings

Company Profile

Company Name:
Autolus Therapeutics PLC
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
753
Office Location:
The Mediaworks,191 Wood Lane,White City,London,Greater London,United Kingdom
Website:
http://www.autolus.com
Zip Code:
W12 7FP
Phone:
44 20 3829 6230
Fax:
- -
Introduction:
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Directors

Name
Position
Christian Itin
Chief Executive Officer and Director
Michael Bonney
Chairman of the Board
Cynthia Butitta
Director
Elisabeth Leiderman
Director
John Berriman
Director
Linda Bain
Director
Ravi Rao
Director
Robert Azelby
Director
Robert Iannone
Director
Ryan Richardson
Director
William Young
Director

Shareholders

Name
Position
Christian Itin
Chief Executive Officer and Director
Christopher Vann
Chief Operating Officer and Senior Vice President
Alex Driggs
General Counsel and Senior Vice President, Legal Affairs
Alexander Swan
Chief Human Resources Officer and Senior Vice President
Christopher Williams
Chief Business Development Officer and Senior Vice President
Cintia Piccina
Senior Vice President and US Chief Commercial Officer and Country GM
Martin Pulé
Chief Scientific Officer and Senior Vice President
Matthias Will
Chief Development Officer and Senior Vice President
Miranda Neville
Chief Technology Officer and Senior Vice President
Patrick McIlvenny
Chief Accounting Officer and Senior Vice President, Finance
Robert Dolski
Chief Financial Officer and Senior Vice President